PEPFAR, a global program to combat AIDS, faces an existential threat due to partisan politics, but Congress has an opportunity to reform the program and ensure its continued success.

Lynae Darbes, PhD, presented research on the effectiveness of a home-based intervention for HIV prevention among couples ...

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...

March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year.

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...

According to the health department’s recent report, among the 2,394 HIV-positive individuals in Mau, 1,147 are men, 1,151 are women, and 85 are children.

The Trump administration has cut around 100 employees, or roughly 10%, of the federal agency that oversees mental and ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...